The Influence of Cross-Reactive T Cells in COVID-19

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Mar 28

PMID 38540178

Authors

Peter J Eggenhuizen

Joshua D Ooi

Affiliations

Soon will be listed here.

Abstract

Memory T cells form from the adaptive immune response to historic infections or vaccinations. Some memory T cells have the potential to recognise unrelated pathogens like severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and generate cross-reactive immune responses. Notably, such T cell cross-reactivity has been observed between SARS-CoV-2 and other human coronaviruses. T cell cross-reactivity has also been observed between SARS-CoV-2 variants from unrelated microbes and unrelated vaccinations against influenza A, tuberculosis and measles, mumps and rubella. Extensive research and debate is underway to understand the mechanism and role of T cell cross-reactivity and how it relates to Coronavirus disease 2019 (COVID-19) outcomes. Here, we review the evidence for the ability of pre-existing memory T cells to cross-react with SARS-CoV-2. We discuss the latest findings on the impact of T cell cross-reactivity and the extent to which it can cross-protect from COVID-19.

Citing Articles

The Role of Memory T-Cell Mediated Immunity in Long-term COVID-19: Effects of Vaccination Status.

Kurmangaliyeva S, Madenbayeva A, Urazayeva S, Bazargaliyev Y, Kudabayeva K, Kurmangaliyev K Iran J Med Sci. 2025; 50(2):61-68.

PMID: 40026299 PMC: 11870859. DOI: 10.30476/ijms.2024.104003.3744.

Bioinformatic Tools for Studying the Cellular Immune Response to SARS-CoV-2, Vaccine Efficacy, and Future Pandemics at the Global Population Level.

Lopez D, Zumarraga J Int J Mol Sci. 2025; 25(24.

PMID: 39769240 PMC: 11678114. DOI: 10.3390/ijms252413477.

QuantiFERON SARS-CoV-2 assay for the evaluation of cellular immunity after immunization with mRNA SARS-CoV-2 vaccines: a systematic review and meta-analysis.

Dourdouna M, Kourlaba G, Michos A Immunol Res. 2024; 73(1):25.

PMID: 39729138 DOI: 10.1007/s12026-024-09570-w.

References

Altmann D, Boyton R . SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci Immunol. 2020; 5(49). DOI: 10.1126/sciimmunol.abd6160. View

Kundu R, Narean J, Wang L, Fenn J, Pillay T, Fernandez N . Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat Commun. 2022; 13(1):80. PMC: 8748880. DOI: 10.1038/s41467-021-27674-x. View

Saini S, Hersby D, Tamhane T, Povlsen H, Amaya Hernandez S, Nielsen M . SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8 T cell activation in COVID-19 patients. Sci Immunol. 2021; 6(58). PMC: 8139428. DOI: 10.1126/sciimmunol.abf7550. View

Wu L, Wang N, Chang Y, Tian X, Na D, Zhang L . Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2008; 13(10):1562-4. PMC: 2851497. DOI: 10.3201/eid1310.070576. View

Sette A, Saphire E . Inducing broad-based immunity against viruses with pandemic potential. Immunity. 2022; 55(5):738-748. PMC: 10286218. DOI: 10.1016/j.immuni.2022.04.010. View

Juno J, Tan H, Lee W, Reynaldi A, Kelly H, Wragg K . Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020; 26(9):1428-1434. DOI: 10.1038/s41591-020-0995-0. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Mysore V, Cullere X, Settles M, Ji X, Kattan M, Desjardins M . Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens. Med. 2021; 2(9):1050-1071.e7. PMC: 8363466. DOI: 10.1016/j.medj.2021.08.004. View

Higgins J, Soares-Weiser K, Lopez-Lopez J, Kakourou A, Chaplin K, Christensen H . Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016; 355:i5170. PMC: 5063034. DOI: 10.1136/bmj.i5170. View

10.

Fischer W, Giorgi E, Chakraborty S, Nguyen K, Bhattacharya T, Theiler J . HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. Cell Host Microbe. 2021; 29(7):1093-1110. PMC: 8173590. DOI: 10.1016/j.chom.2021.05.012. View

11.

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

12.

Tang F, Quan Y, Xin Z, Wrammert J, Ma M, Lv H . Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011; 186(12):7264-8. DOI: 10.4049/jimmunol.0903490. View

13.

Pittet L, Messina N, Orsini F, Moore C, Abruzzo V, Barry S . Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers. N Engl J Med. 2023; 388(17):1582-1596. PMC: 10497190. DOI: 10.1056/NEJMoa2212616. View

14.

Upton C, Van Wijk R, Mockeliunas L, Simonsson U, McHarry K, van den Hoogen G . Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial. EClinicalMedicine. 2022; 48:101414. PMC: 9098089. DOI: 10.1016/j.eclinm.2022.101414. View

15.

Kumar N, Padmapriyadarsini C, Rajamanickam A, Bhavani P, Nancy A, Jeyadeepa B . BCG vaccination induces enhanced frequencies of dendritic cells and altered plasma levels of type I and type III interferons in elderly individuals. Int J Infect Dis. 2021; 110:98-104. PMC: 8295056. DOI: 10.1016/j.ijid.2021.07.041. View

16.

Loyal L, Braun J, Henze L, Kruse B, Dingeldey M, Reimer U . Cross-reactive CD4 T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science. 2021; 374(6564):eabh1823. PMC: 10026850. DOI: 10.1126/science.abh1823. View

17.

Ng K, Faulkner N, Cornish G, Rosa A, Harvey R, Hussain S . Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020; 370(6522):1339-1343. PMC: 7857411. DOI: 10.1126/science.abe1107. View

18.

Alves R, Timis J, Miller R, Valentine K, Pinto P, Gonzalez A . Human coronavirus OC43-elicited CD4 T cells protect against SARS-CoV-2 in HLA transgenic mice. Nat Commun. 2024; 15(1):787. PMC: 10817949. DOI: 10.1038/s41467-024-45043-2. View

19.

Eggenhuizen P, Ng B, Chang J, Fell A, Cheong R, Wong W . BCG Vaccine Derived Peptides Induce SARS-CoV-2 T Cell Cross-Reactivity. Front Immunol. 2021; 12:692729. PMC: 8374943. DOI: 10.3389/fimmu.2021.692729. View

20.

Tarabini R, Rigo M, Fonseca A, Rubin F, Belle R, Kavraki L . Large-Scale Structure-Based Screening of Potential T Cell Cross-Reactivities Involving Peptide-Targets From BCG Vaccine and SARS-CoV-2. Front Immunol. 2022; 12:812176. PMC: 8793865. DOI: 10.3389/fimmu.2021.812176. View